Niagen Bioscience, Inc.
NAGE
$7.38
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 37.41% | 31.21% | 11.89% | -1.79% | 0.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.41% | 31.21% | 11.89% | -1.79% | 0.95% |
| Cost of Revenue | 32.32% | 24.10% | 13.54% | -3.77% | -8.03% |
| Gross Profit | 40.66% | 35.68% | 10.82% | -0.46% | 7.66% |
| SG&A Expenses | -18.21% | 12.40% | -5.07% | -15.40% | -1.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.04% | 16.16% | 1.57% | -6.69% | -4.80% |
| Operating Income | 4,332.74% | 239.67% | 88.95% | 62.86% | 88.37% |
| Income Before Tax | 6,464.91% | 295.83% | 99.32% | 74.13% | 108.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6,197.37% | 295.83% | 99.32% | 74.13% | 108.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6,197.37% | 295.83% | 99.32% | 74.13% | 108.04% |
| EBIT | 4,332.74% | 239.67% | 88.95% | 62.86% | 88.37% |
| EBITDA | 15,108.33% | 306.17% | 97.60% | 69.69% | 104.07% |
| EPS Basic | 6,120.00% | 292.97% | 99.32% | 74.41% | 107.81% |
| Normalized Basic EPS | 6,655.56% | 292.50% | 99.45% | 74.21% | 107.50% |
| EPS Diluted | -- | 256.25% | 99.33% | 74.41% | 100.00% |
| Normalized Diluted EPS | 6,266.67% | 288.75% | 99.45% | 74.21% | 107.50% |
| Average Basic Shares Outstanding | 2.43% | 1.23% | 0.79% | 0.58% | 1.68% |
| Average Diluted Shares Outstanding | 8.71% | 3.62% | 0.79% | 0.58% | 1.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |